English
简体中文
Total: £ 56.28
Published Date: 2026-03-30 | Pages: 155 | Tables: 145 | Medical Care
The global Hepatitis Delta Virus (HDV) Infection market was valued at US$ 2058 million in 2025 and is anticipated to reach US$ 12630 million by 2032, at a CAGR of 30.0% from 2026 to 2032.
Hepatitis D, also known as delta hepatitis, is a liver infection caused by the Hepatitis D virus (HDV). It is considered a satellite virus, as it requires the presence of the Hepatitis B virus (HBV) to replicate and cause infection. HDV infects individuals either as a co-infection with HBV or as a superinfection in those already infected with HBV. Hepatitis D is caused by the HDV, which can only infect individuals already infected with HBV. HDV can spread through contact with infected blood or body fluids, similar to HBV transmission routes. Injection drug use, exposure to infected blood, or unprotected sexual contact with an HBV/HDV-infected person are common risk factors for acquiring Hepatitis D.
The increasing global prevalence of HDV infection is a significant market driver that is boosting the Market CAGR. HDV infection, which occurs along with hepatitis B virus (HBV) infection, is considered the most severe form of viral hepatitis, resulting in increased morbidity and fatality rates. The World Health Organization (WHO) estimates that over 15-20 million people globally are chronically infected with HDV. This growing incidence of HDV infection highlights the critical need for improved diagnoses, therapies, and preventive measures, which will drive market expansion.
This report delivers a comprehensive overview of the global Hepatitis Delta Virus (HDV) Infection market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hepatitis Delta Virus (HDV) Infection. The Hepatitis Delta Virus (HDV) Infection market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Hepatitis Delta Virus (HDV) Infection market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Hepatitis Delta Virus (HDV) Infection manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
BIOSIDUS
Hoffmann-La Roche Ltd.
Zydus Cadila
NanoGen Healthcare Pvt. Ltd.
AMEGA Biotech
Rhein-Minapharm
PROBIOMED SA de CV
3SBio Group
Eiger BioPharmaceuticals
Arrowhead Pharmaceuticals, Inc
MYR Pharmaceuticals
Hepatera
Janssen Biopharmaceuticals
Antios Therapeutics, Inc.
PharmaEssentia Corporation
Replicor, Janssen Pharmaceuticals, Inc
Apotex Corp.
Mylan N.V
Aurobindo Pharma Limited
Gilead Sciences, Inc.
GlaxoSmithKline
Segment by Type
Acute Hepatitis D
Chronic Hepatitis D
Segment by Application
Clinic
Hospital
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Hepatitis Delta Virus (HDV) Infection companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatitis Delta Virus (HDV) Infection Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Acute Hepatitis D
1.2.3 Chronic Hepatitis D
1.3 Market by Application
1.3.1 Global Hepatitis Delta Virus (HDV) Infection Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatitis Delta Virus (HDV) Infection Market Perspective (2021–2032)
2.2 Global Hepatitis Delta Virus (HDV) Infection Growth Trends by Region
2.2.1 Global Hepatitis Delta Virus (HDV) Infection Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Hepatitis Delta Virus (HDV) Infection Historic Market Size by Region (2021–2026)
2.2.3 Hepatitis Delta Virus (HDV) Infection Forecasted Market Size by Region (2027–2032)
2.3 Hepatitis Delta Virus (HDV) Infection Market Dynamics
2.3.1 Hepatitis Delta Virus (HDV) Infection Industry Trends
2.3.2 Hepatitis Delta Virus (HDV) Infection Market Drivers
2.3.3 Hepatitis Delta Virus (HDV) Infection Market Challenges
2.3.4 Hepatitis Delta Virus (HDV) Infection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatitis Delta Virus (HDV) Infection Players by Revenue
3.1.1 Global Top Hepatitis Delta Virus (HDV) Infection Players by Revenue (2021–2026)
3.1.2 Global Hepatitis Delta Virus (HDV) Infection Revenue Market Share by Players (2021–2026)
3.2 Global Top Hepatitis Delta Virus (HDV) Infection Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Hepatitis Delta Virus (HDV) Infection Revenue
3.4 Global Hepatitis Delta Virus (HDV) Infection Market Concentration Ratio
3.4.1 Global Hepatitis Delta Virus (HDV) Infection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatitis Delta Virus (HDV) Infection Revenue in 2025
3.5 Global Key Players of Hepatitis Delta Virus (HDV) Infection Head Offices and Areas Served
3.6 Global Key Players of Hepatitis Delta Virus (HDV) Infection, Products and Applications
3.7 Global Key Players of Hepatitis Delta Virus (HDV) Infection, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Hepatitis Delta Virus (HDV) Infection Breakdown Data by Type
4.1 Global Hepatitis Delta Virus (HDV) Infection Historic Market Size by Type (2021–2026)
4.2 Global Hepatitis Delta Virus (HDV) Infection Forecasted Market Size by Type (2027–2032)
5 Hepatitis Delta Virus (HDV) Infection Breakdown Data by Application
5.1 Global Hepatitis Delta Virus (HDV) Infection Historic Market Size by Application (2021–2026)
5.2 Global Hepatitis Delta Virus (HDV) Infection Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Hepatitis Delta Virus (HDV) Infection Market Size (2021–2032)
6.2 North America Hepatitis Delta Virus (HDV) Infection Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Hepatitis Delta Virus (HDV) Infection Market Size by Country (2021–2026)
6.4 North America Hepatitis Delta Virus (HDV) Infection Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hepatitis Delta Virus (HDV) Infection Market Size (2021–2032)
7.2 Europe Hepatitis Delta Virus (HDV) Infection Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Hepatitis Delta Virus (HDV) Infection Market Size by Country (2021–2026)
7.4 Europe Hepatitis Delta Virus (HDV) Infection Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Size (2021–2032)
8.2 Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Size by Region (2021–2026)
8.4 Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Hepatitis Delta Virus (HDV) Infection Market Size (2021–2032)
9.2 Latin America Hepatitis Delta Virus (HDV) Infection Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Hepatitis Delta Virus (HDV) Infection Market Size by Country (2021–2026)
9.4 Latin America Hepatitis Delta Virus (HDV) Infection Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Size (2021–2032)
10.2 Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Size by Country (2021–2026)
10.4 Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BIOSIDUS
11.1.1 BIOSIDUS Company Details
11.1.2 BIOSIDUS Business Overview
11.1.3 BIOSIDUS Hepatitis Delta Virus (HDV) Infection Introduction
11.1.4 BIOSIDUS Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.1.5 BIOSIDUS Recent Development
11.2 Hoffmann-La Roche Ltd.
11.2.1 Hoffmann-La Roche Ltd. Company Details
11.2.2 Hoffmann-La Roche Ltd. Business Overview
11.2.3 Hoffmann-La Roche Ltd. Hepatitis Delta Virus (HDV) Infection Introduction
11.2.4 Hoffmann-La Roche Ltd. Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.2.5 Hoffmann-La Roche Ltd. Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Details
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila Hepatitis Delta Virus (HDV) Infection Introduction
11.3.4 Zydus Cadila Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.3.5 Zydus Cadila Recent Development
11.4 NanoGen Healthcare Pvt. Ltd.
11.4.1 NanoGen Healthcare Pvt. Ltd. Company Details
11.4.2 NanoGen Healthcare Pvt. Ltd. Business Overview
11.4.3 NanoGen Healthcare Pvt. Ltd. Hepatitis Delta Virus (HDV) Infection Introduction
11.4.4 NanoGen Healthcare Pvt. Ltd. Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.4.5 NanoGen Healthcare Pvt. Ltd. Recent Development
11.5 AMEGA Biotech
11.5.1 AMEGA Biotech Company Details
11.5.2 AMEGA Biotech Business Overview
11.5.3 AMEGA Biotech Hepatitis Delta Virus (HDV) Infection Introduction
11.5.4 AMEGA Biotech Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.5.5 AMEGA Biotech Recent Development
11.6 Rhein-Minapharm
11.6.1 Rhein-Minapharm Company Details
11.6.2 Rhein-Minapharm Business Overview
11.6.3 Rhein-Minapharm Hepatitis Delta Virus (HDV) Infection Introduction
11.6.4 Rhein-Minapharm Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.6.5 Rhein-Minapharm Recent Development
11.7 PROBIOMED SA de CV
11.7.1 PROBIOMED SA de CV Company Details
11.7.2 PROBIOMED SA de CV Business Overview
11.7.3 PROBIOMED SA de CV Hepatitis Delta Virus (HDV) Infection Introduction
11.7.4 PROBIOMED SA de CV Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.7.5 PROBIOMED SA de CV Recent Development
11.8 3SBio Group
11.8.1 3SBio Group Company Details
11.8.2 3SBio Group Business Overview
11.8.3 3SBio Group Hepatitis Delta Virus (HDV) Infection Introduction
11.8.4 3SBio Group Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.8.5 3SBio Group Recent Development
11.9 Eiger BioPharmaceuticals
11.9.1 Eiger BioPharmaceuticals Company Details
11.9.2 Eiger BioPharmaceuticals Business Overview
11.9.3 Eiger BioPharmaceuticals Hepatitis Delta Virus (HDV) Infection Introduction
11.9.4 Eiger BioPharmaceuticals Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.9.5 Eiger BioPharmaceuticals Recent Development
11.10 Arrowhead Pharmaceuticals, Inc
11.10.1 Arrowhead Pharmaceuticals, Inc Company Details
11.10.2 Arrowhead Pharmaceuticals, Inc Business Overview
11.10.3 Arrowhead Pharmaceuticals, Inc Hepatitis Delta Virus (HDV) Infection Introduction
11.10.4 Arrowhead Pharmaceuticals, Inc Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.10.5 Arrowhead Pharmaceuticals, Inc Recent Development
11.11 MYR Pharmaceuticals
11.11.1 MYR Pharmaceuticals Company Details
11.11.2 MYR Pharmaceuticals Business Overview
11.11.3 MYR Pharmaceuticals Hepatitis Delta Virus (HDV) Infection Introduction
11.11.4 MYR Pharmaceuticals Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.11.5 MYR Pharmaceuticals Recent Development
11.12 Hepatera
11.12.1 Hepatera Company Details
11.12.2 Hepatera Business Overview
11.12.3 Hepatera Hepatitis Delta Virus (HDV) Infection Introduction
11.12.4 Hepatera Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.12.5 Hepatera Recent Development
11.13 Janssen Biopharmaceuticals
11.13.1 Janssen Biopharmaceuticals Company Details
11.13.2 Janssen Biopharmaceuticals Business Overview
11.13.3 Janssen Biopharmaceuticals Hepatitis Delta Virus (HDV) Infection Introduction
11.13.4 Janssen Biopharmaceuticals Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.13.5 Janssen Biopharmaceuticals Recent Development
11.14 Antios Therapeutics, Inc.
11.14.1 Antios Therapeutics, Inc. Company Details
11.14.2 Antios Therapeutics, Inc. Business Overview
11.14.3 Antios Therapeutics, Inc. Hepatitis Delta Virus (HDV) Infection Introduction
11.14.4 Antios Therapeutics, Inc. Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.14.5 Antios Therapeutics, Inc. Recent Development
11.15 PharmaEssentia Corporation
11.15.1 PharmaEssentia Corporation Company Details
11.15.2 PharmaEssentia Corporation Business Overview
11.15.3 PharmaEssentia Corporation Hepatitis Delta Virus (HDV) Infection Introduction
11.15.4 PharmaEssentia Corporation Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.15.5 PharmaEssentia Corporation Recent Development
11.16 Replicor, Janssen Pharmaceuticals, Inc
11.16.1 Replicor, Janssen Pharmaceuticals, Inc Company Details
11.16.2 Replicor, Janssen Pharmaceuticals, Inc Business Overview
11.16.3 Replicor, Janssen Pharmaceuticals, Inc Hepatitis Delta Virus (HDV) Infection Introduction
11.16.4 Replicor, Janssen Pharmaceuticals, Inc Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.16.5 Replicor, Janssen Pharmaceuticals, Inc Recent Development
11.17 Apotex Corp.
11.17.1 Apotex Corp. Company Details
11.17.2 Apotex Corp. Business Overview
11.17.3 Apotex Corp. Hepatitis Delta Virus (HDV) Infection Introduction
11.17.4 Apotex Corp. Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.17.5 Apotex Corp. Recent Development
11.18 Mylan N.V
11.18.1 Mylan N.V Company Details
11.18.2 Mylan N.V Business Overview
11.18.3 Mylan N.V Hepatitis Delta Virus (HDV) Infection Introduction
11.18.4 Mylan N.V Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.18.5 Mylan N.V Recent Development
11.19 Aurobindo Pharma Limited
11.19.1 Aurobindo Pharma Limited Company Details
11.19.2 Aurobindo Pharma Limited Business Overview
11.19.3 Aurobindo Pharma Limited Hepatitis Delta Virus (HDV) Infection Introduction
11.19.4 Aurobindo Pharma Limited Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.19.5 Aurobindo Pharma Limited Recent Development
11.20 Gilead Sciences, Inc.
11.20.1 Gilead Sciences, Inc. Company Details
11.20.2 Gilead Sciences, Inc. Business Overview
11.20.3 Gilead Sciences, Inc. Hepatitis Delta Virus (HDV) Infection Introduction
11.20.4 Gilead Sciences, Inc. Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.20.5 Gilead Sciences, Inc. Recent Development
11.21 GlaxoSmithKline
11.21.1 GlaxoSmithKline Company Details
11.21.2 GlaxoSmithKline Business Overview
11.21.3 GlaxoSmithKline Hepatitis Delta Virus (HDV) Infection Introduction
11.21.4 GlaxoSmithKline Revenue in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
11.21.5 GlaxoSmithKline Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Hepatitis Delta Virus (HDV) Infection Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Acute Hepatitis D
Table 3. Key Players of Chronic Hepatitis D
Table 4. Global Hepatitis Delta Virus (HDV) Infection Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Hepatitis Delta Virus (HDV) Infection Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Hepatitis Delta Virus (HDV) Infection Market Size by Region (US$ Million), 2021–2026
Table 7. Global Hepatitis Delta Virus (HDV) Infection Market Share by Region (2021–2026)
Table 8. Global Hepatitis Delta Virus (HDV) Infection Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Hepatitis Delta Virus (HDV) Infection Market Share by Region (2027–2032)
Table 10. Hepatitis Delta Virus (HDV) Infection Market Trends
Table 11. Hepatitis Delta Virus (HDV) Infection Market Drivers
Table 12. Hepatitis Delta Virus (HDV) Infection Market Challenges
Table 13. Hepatitis Delta Virus (HDV) Infection Market Restraints
Table 14. Global Hepatitis Delta Virus (HDV) Infection Revenue by Players (US$ Million), 2021–2026
Table 15. Global Hepatitis Delta Virus (HDV) Infection Market Share by Players (2021–2026)
Table 16. Global Top Hepatitis Delta Virus (HDV) Infection Players by Tier (Tier 1, Tier 2, and Tier 3), based on Hepatitis Delta Virus (HDV) Infection Revenue, 2025
Table 17. Ranking of Global Top Hepatitis Delta Virus (HDV) Infection Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Hepatitis Delta Virus (HDV) Infection Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Hepatitis Delta Virus (HDV) Infection, Headquarters and Area Served
Table 20. Global Key Players of Hepatitis Delta Virus (HDV) Infection, Products and Applications
Table 21. Global Key Players of Hepatitis Delta Virus (HDV) Infection, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Hepatitis Delta Virus (HDV) Infection Market Size by Type (US$ Million), 2021–2026
Table 24. Global Hepatitis Delta Virus (HDV) Infection Revenue Market Share by Type (2021–2026)
Table 25. Global Hepatitis Delta Virus (HDV) Infection Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Hepatitis Delta Virus (HDV) Infection Revenue Market Share by Type (2027–2032)
Table 27. Global Hepatitis Delta Virus (HDV) Infection Market Size by Application (US$ Million), 2021–2026
Table 28. Global Hepatitis Delta Virus (HDV) Infection Revenue Market Share by Application (2021–2026)
Table 29. Global Hepatitis Delta Virus (HDV) Infection Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Hepatitis Delta Virus (HDV) Infection Revenue Market Share by Application (2027–2032)
Table 31. North America Hepatitis Delta Virus (HDV) Infection Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2021–2026
Table 33. North America Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Hepatitis Delta Virus (HDV) Infection Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Hepatitis Delta Virus (HDV) Infection Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Size by Country (US$ Million), 2027–2032
Table 46. BIOSIDUS Company Details
Table 47. BIOSIDUS Business Overview
Table 48. BIOSIDUS Hepatitis Delta Virus (HDV) Infection Product
Table 49. BIOSIDUS Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 50. BIOSIDUS Recent Development
Table 51. Hoffmann-La Roche Ltd. Company Details
Table 52. Hoffmann-La Roche Ltd. Business Overview
Table 53. Hoffmann-La Roche Ltd. Hepatitis Delta Virus (HDV) Infection Product
Table 54. Hoffmann-La Roche Ltd. Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 55. Hoffmann-La Roche Ltd. Recent Development
Table 56. Zydus Cadila Company Details
Table 57. Zydus Cadila Business Overview
Table 58. Zydus Cadila Hepatitis Delta Virus (HDV) Infection Product
Table 59. Zydus Cadila Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 60. Zydus Cadila Recent Development
Table 61. NanoGen Healthcare Pvt. Ltd. Company Details
Table 62. NanoGen Healthcare Pvt. Ltd. Business Overview
Table 63. NanoGen Healthcare Pvt. Ltd. Hepatitis Delta Virus (HDV) Infection Product
Table 64. NanoGen Healthcare Pvt. Ltd. Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 65. NanoGen Healthcare Pvt. Ltd. Recent Development
Table 66. AMEGA Biotech Company Details
Table 67. AMEGA Biotech Business Overview
Table 68. AMEGA Biotech Hepatitis Delta Virus (HDV) Infection Product
Table 69. AMEGA Biotech Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 70. AMEGA Biotech Recent Development
Table 71. Rhein-Minapharm Company Details
Table 72. Rhein-Minapharm Business Overview
Table 73. Rhein-Minapharm Hepatitis Delta Virus (HDV) Infection Product
Table 74. Rhein-Minapharm Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 75. Rhein-Minapharm Recent Development
Table 76. PROBIOMED SA de CV Company Details
Table 77. PROBIOMED SA de CV Business Overview
Table 78. PROBIOMED SA de CV Hepatitis Delta Virus (HDV) Infection Product
Table 79. PROBIOMED SA de CV Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 80. PROBIOMED SA de CV Recent Development
Table 81. 3SBio Group Company Details
Table 82. 3SBio Group Business Overview
Table 83. 3SBio Group Hepatitis Delta Virus (HDV) Infection Product
Table 84. 3SBio Group Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 85. 3SBio Group Recent Development
Table 86. Eiger BioPharmaceuticals Company Details
Table 87. Eiger BioPharmaceuticals Business Overview
Table 88. Eiger BioPharmaceuticals Hepatitis Delta Virus (HDV) Infection Product
Table 89. Eiger BioPharmaceuticals Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 90. Eiger BioPharmaceuticals Recent Development
Table 91. Arrowhead Pharmaceuticals, Inc Company Details
Table 92. Arrowhead Pharmaceuticals, Inc Business Overview
Table 93. Arrowhead Pharmaceuticals, Inc Hepatitis Delta Virus (HDV) Infection Product
Table 94. Arrowhead Pharmaceuticals, Inc Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 95. Arrowhead Pharmaceuticals, Inc Recent Development
Table 96. MYR Pharmaceuticals Company Details
Table 97. MYR Pharmaceuticals Business Overview
Table 98. MYR Pharmaceuticals Hepatitis Delta Virus (HDV) Infection Product
Table 99. MYR Pharmaceuticals Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 100. MYR Pharmaceuticals Recent Development
Table 101. Hepatera Company Details
Table 102. Hepatera Business Overview
Table 103. Hepatera Hepatitis Delta Virus (HDV) Infection Product
Table 104. Hepatera Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 105. Hepatera Recent Development
Table 106. Janssen Biopharmaceuticals Company Details
Table 107. Janssen Biopharmaceuticals Business Overview
Table 108. Janssen Biopharmaceuticals Hepatitis Delta Virus (HDV) Infection Product
Table 109. Janssen Biopharmaceuticals Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 110. Janssen Biopharmaceuticals Recent Development
Table 111. Antios Therapeutics, Inc. Company Details
Table 112. Antios Therapeutics, Inc. Business Overview
Table 113. Antios Therapeutics, Inc. Hepatitis Delta Virus (HDV) Infection Product
Table 114. Antios Therapeutics, Inc. Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 115. Antios Therapeutics, Inc. Recent Development
Table 116. PharmaEssentia Corporation Company Details
Table 117. PharmaEssentia Corporation Business Overview
Table 118. PharmaEssentia Corporation Hepatitis Delta Virus (HDV) Infection Product
Table 119. PharmaEssentia Corporation Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 120. PharmaEssentia Corporation Recent Development
Table 121. Replicor, Janssen Pharmaceuticals, Inc Company Details
Table 122. Replicor, Janssen Pharmaceuticals, Inc Business Overview
Table 123. Replicor, Janssen Pharmaceuticals, Inc Hepatitis Delta Virus (HDV) Infection Product
Table 124. Replicor, Janssen Pharmaceuticals, Inc Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 125. Replicor, Janssen Pharmaceuticals, Inc Recent Development
Table 126. Apotex Corp. Company Details
Table 127. Apotex Corp. Business Overview
Table 128. Apotex Corp. Hepatitis Delta Virus (HDV) Infection Product
Table 129. Apotex Corp. Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 130. Apotex Corp. Recent Development
Table 131. Mylan N.V Company Details
Table 132. Mylan N.V Business Overview
Table 133. Mylan N.V Hepatitis Delta Virus (HDV) Infection Product
Table 134. Mylan N.V Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 135. Mylan N.V Recent Development
Table 136. Aurobindo Pharma Limited Company Details
Table 137. Aurobindo Pharma Limited Business Overview
Table 138. Aurobindo Pharma Limited Hepatitis Delta Virus (HDV) Infection Product
Table 139. Aurobindo Pharma Limited Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 140. Aurobindo Pharma Limited Recent Development
Table 141. Gilead Sciences, Inc. Company Details
Table 142. Gilead Sciences, Inc. Business Overview
Table 143. Gilead Sciences, Inc. Hepatitis Delta Virus (HDV) Infection Product
Table 144. Gilead Sciences, Inc. Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 145. Gilead Sciences, Inc. Recent Development
Table 146. GlaxoSmithKline Company Details
Table 147. GlaxoSmithKline Business Overview
Table 148. GlaxoSmithKline Hepatitis Delta Virus (HDV) Infection Product
Table 149. GlaxoSmithKline Revenue in Hepatitis Delta Virus (HDV) Infection Business (US$ Million), 2021–2026
Table 150. GlaxoSmithKline Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
Table 154. Authors List of This Report
List of Figures
Figure 1. Hepatitis Delta Virus (HDV) Infection Picture
Figure 2. Global Hepatitis Delta Virus (HDV) Infection Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Hepatitis Delta Virus (HDV) Infection Market Share by Type: 2025 vs 2032
Figure 4. Acute Hepatitis D Features
Figure 5. Chronic Hepatitis D Features
Figure 6. Global Hepatitis Delta Virus (HDV) Infection Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Hepatitis Delta Virus (HDV) Infection Market Share by Application: 2025 vs 2032
Figure 8. Clinic Case Studies
Figure 9. Hospital Case Studies
Figure 10. Others Case Studies
Figure 11. Hepatitis Delta Virus (HDV) Infection Report Years Considered
Figure 12. Global Hepatitis Delta Virus (HDV) Infection Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 13. Global Hepatitis Delta Virus (HDV) Infection Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Hepatitis Delta Virus (HDV) Infection Market Share by Region: 2025 vs 2032
Figure 15. Global Hepatitis Delta Virus (HDV) Infection Market Share by Players in 2025
Figure 16. Global Hepatitis Delta Virus (HDV) Infection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Hepatitis Delta Virus (HDV) Infection Revenue in 2025
Figure 18. North America Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 19. North America Hepatitis Delta Virus (HDV) Infection Market Share by Country (2021–2032)
Figure 20. United States Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Canada Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Hepatitis Delta Virus (HDV) Infection Market Share by Country (2021–2032)
Figure 24. Germany Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. France Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. U.K. Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Italy Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Russia Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Ireland Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Hepatitis Delta Virus (HDV) Infection Market Share by Region (2021–2032)
Figure 32. China Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Japan Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. South Korea Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Southeast Asia Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. India Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Australia & New Zealand Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Hepatitis Delta Virus (HDV) Infection Market Share by Country (2021–2032)
Figure 40. Mexico Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Brazil Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Hepatitis Delta Virus (HDV) Infection Market Share by Country (2021–2032)
Figure 44. Israel Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Saudi Arabia Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. UAE Hepatitis Delta Virus (HDV) Infection Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. BIOSIDUS Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 48. Hoffmann-La Roche Ltd. Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 49. Zydus Cadila Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 50. NanoGen Healthcare Pvt. Ltd. Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 51. AMEGA Biotech Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 52. Rhein-Minapharm Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 53. PROBIOMED SA de CV Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 54. 3SBio Group Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 55. Eiger BioPharmaceuticals Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 56. Arrowhead Pharmaceuticals, Inc Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 57. MYR Pharmaceuticals Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 58. Hepatera Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 59. Janssen Biopharmaceuticals Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 60. Antios Therapeutics, Inc. Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 61. PharmaEssentia Corporation Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 62. Replicor, Janssen Pharmaceuticals, Inc Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 63. Apotex Corp. Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 64. Mylan N.V Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 65. Aurobindo Pharma Limited Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 66. Gilead Sciences, Inc. Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Hepatitis Delta Virus (HDV) Infection Business (2021–2026)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
